Clinical Trials on Hepatic Neoplasm

Total 110283 results

Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of Danicopan in Participants With Hepatic Impairment

Hepatic Impairment

United States
Janssen Research & Development, LLC

Terminated

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib

Hepatic Impairment

Germany
Daiichi Sankyo, Inc.

Completed

Study of Single-dose DS-3201b in Participants With Hepatic Impairment

Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic Function

Hepatic Impairment

United States
Celgene

Completed

A Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairment Compared With Healthy Subjects

Hepatic Impairment

United States
Eisai Inc.

Completed

Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment

Hepatic Impairment

United States
Pfizer

Completed

Study of PF-05221304 in Subjects With Varying Degrees of Hepatic Impairment

Hepatic Impairment

United States, Belgium, Czechia, Slovakia
Aragon Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic Function

Hepatic Impairment

United States
Ipsen

Completed

Study to Evaluate a Dose of Telotristat Etiprate in Male and Female With Mild, Moderate and Severe Hepatic Insufficiency and Matched Healthy Subjects

Hepatic Impairment

Moldova, Republic of, Romania
Midwestern Regional Medical Center

Terminated

Compassionate Use of Omegaven® in the Treatment of Parenteral Nutrition Induced Hepatic Injury

Cancer | Hepatic Injury

United States
Eli Lilly and Company
AstraZeneca

Withdrawn

A Study of LY3314814 in Participants With Liver Impairment

Hepatic Impairment

United States
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Safety and Pharmacokinetics/Pharmacodynamics of SHR3824 in Patients With Hepatic Impairment

Hepatic Impairment

China
Novartis Pharmaceuticals

Completed

A Study of LCZ696 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers

Hepatic Impairment

Germany
Melinta Therapeutics, Inc.

Completed

Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic Impairment

Hepatic Impairment

United States
Samsung Electronics

Terminated

Evaluation of the Samsung LABGEO PT10 Hepatic Panel in a Point-of-Care Setting

Hepatic Disease

United States
FORUM Pharmaceuticals Inc
PRA Health Sciences

Completed

EVP-6124 Hepatic Impairment Study

Hepatic Impairment

Czech Republic, Poland, Slovakia
LG Life Sciences

Completed

Influence of Hepatic Impairment on Pharmacokinetic (PK) and Pharmacodynamic (PD) of Gemigliptin PK and PD After Multiple Oral Doses in Healthy White Volunteers

Hepatic Impairment

Germany
Janssen Research & Development, LLC

Completed

A Pharmacokinetic Study of Abiraterone Acetate in Patients With Severe Hepatic Impairment Compared to Patients With Normal Hepatic Function

Hepatic Impairment

United States
Sanofi

Completed

Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild and Moderate Hepatic Impairment

Hepatic Impairment

United States
Sanofi

Completed

Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic Impairment

Hepatic Impairment

United States
Newron Pharmaceuticals SPA

Completed

A Study to Assess the Effect of Hepatic Impairment on Safinamide Pharmacokinetics

Hepatic Impairment

Germany
Cephalon

Completed

A Study to Evaluate the Pharmacokinetics of the Hydrocodone Extended-Release Tablet (CEP-33237) in Subjects With Normal Hepatic Function and Subjects With Moderate Hepatic Impairment

Hepatic Impairment

United States
Biogen

Completed

BG9928 in Subjects With Hepatic Impairment

Hepatic Impairment

United States
University Hospital, Lille

Recruiting

Comparison of Inflammatory Profiles and Regenerative Potential in Alcoholic Liver Disease (TargetOH)

Liver Diseases | Acute on Chronic Hepatic Failure

France
Johannes Gutenberg University Mainz

Unknown

Cerebrovascular Autoregulation During and After Liver Transplantation (dARICULtx)

Liver Failure | Cerebrovascular Disorders | Encephalopathy, Hepatic

Germany
Postgraduate Institute of Medical Education and...

Unknown

Efficacy of Sildenafil in the Improvement of Cognition and Quality of Life in Patients With Cirrhosis of Liver. A Proof of Concept Study.

Hepatic Encephalopathy.

India
Shanghai Zhongshan Hospital
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.

Hepatic Carcinoma

China
Institute of Nuclear Energy Research, Taiwan

Completed

to Assess the Accuracy and Reliability of the Ga68-Dolacga Positron Emission Tomography Compared to Computer Tomography Volumetry and Indocyanine Green Retention Test for Measurement of Liver Reserve

Hepatic Carcinoma

Taiwan
AstraZeneca

Recruiting

A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693

Hepatic Impairment

United States
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy Subject

Hepatic Impairment

China
CTI BioPharma
PPD

Recruiting

Study to Evaluate the Safety, Tolerability, and PK of Pacritinib

Hepatic Impairment

United States
Eisai Co., Ltd.

Recruiting

Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants

Hepatic Impairment

Japan
Novartis Pharmaceuticals

Completed

A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Hepatic Impairment Compared With Matched Healthy Participants

Hepatic Impairment

Hungary
Chipscreen Biosciences, Ltd.

Completed

Pharmacokinetics of Chiglitazar in Subjects With Hepatic Impairment and Normal Hepatic Function

Hepatic Impairment

China
SK Life Science, Inc.

Completed

Safety Study of Cenobamate in Subjects With Normal Hepatic Function and Subjects With Severe Hepatic Impairment

Hepatic Impairment

Poland, Slovakia
Novartis Pharmaceuticals
Pharmaceutical Research Associates

Withdrawn

Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants

Hepatic Impairment
Institut de Recherches Internationales Servier

Completed

A Study of Vorasidenib in Participants With Moderate or Mild Hepatic Impairment and Matched Participants With Normal Hepatic Function

Hepatic Impairment

United States
Reata, a wholly owned subsidiary of Biogen

Completed

A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function

Hepatic Impairment

United States
Pfizer

Completed

Single-Dose PK and Safety Study of GBT440 in Subjects With Hepatic Impairment

Hepatic Impairment

United States
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Hepatic Impairment

Hepatic Impairment

China
Concert Pharmaceuticals

Completed

Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of CTP-543

Hepatic Impairment

United States
Janssen Research & Development, LLC

Terminated

A Study of JNJ-53718678 in Participants With Hepatic Impairment

Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

Pharmacokinetics of BAF312 in Patients With Hepatic Impairment

Hepatic Impairment

Hungary, Russian Federation
Sichuan Haisco Pharmaceutical Group Co., Ltd
The First Hospital of Jilin University

Completed

Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Patients With Hepatic Impairment

Hepatic Impairment

China
Novartis Pharmaceuticals

Completed

INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function

Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects

Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

A Study to Evaluate the Pharmacokinetics of AFQ056 in Subjects With Hepatic Impairment Compared to Healthy Subjects

Hepatic Impairment

Germany, United States, Hungary
Novartis Pharmaceuticals

Terminated

Pharmacokinetics of Dabrafenib in Subjects With Hepatic Impairment

Hepatic Impairment

United States
Janssen Sciences Ireland UC

Completed

A Study to Evaluate the Effect of Hepatic Impairment on JNJ-73763989

Hepatic Impairment

Germany
Celgene

Completed

A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.

Hepatic Impairment

United States

3

Subscribe